March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, ...

Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing its findings in talks and posters being ...

While 2025 has not been a banner year for biopharma dealmaking, antibodies that bind two or more molecular targets—so-called multispecifics—have taken center stage. The top three licensing deals and ...

Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...